You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection
|
|---|---|
| Published in |
Hepatology, April 2017
|
| DOI | 10.1002/hep.29005 |
| Pubmed ID | |
| Authors |
Kris V. Kowdley, Vinay Sundaram, Christie Y. Jeon, Kamran Qureshi, Nyan L. Latt, Amandeep Sahota, Stephen Lott, Michael P. Curry, Naoky Tsai, Nathorn Chaiyakunapruk, Yoori Lee, Jorg Petersen, Peter Buggisch |
| Abstract |
Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus (HCV) infected patients who are treatment naive, non-cirrhotic and have pre-treatment viral load < 6 million IU/ml. The effectiveness of this regimen, however, has not been fully confirmed by real-world experience. Using data from real-world cohorts, we aimed to determine the effectiveness of 8 weeks of LDV/SOF treatment, examine variables associated with relapse after treatment with this regimen, and compare the effectiveness of 8 weeks and 12 weeks of LDV/SOF treatment. To evaluate the effectiveness of 8 weeks of therapy and characteristics associated with relapse, we utilized individual patient data from IFI Institut für Interdisziplinäre Medizin (IFI), Burmans pharmacy, and Kaiser Permanente Southern California. All patients had fibrosis staging assessed with biopsy, transient elastography or serum biomarkers. We also performed a systematic review and meta-analysis of 6 additional real world cohorts, to compare effectiveness of 8 weeks to 12 weeks duration. In our pooled data analysis, 634 patients were treated for 8 weeks with LDV/SOF, of which all patients had outcomes of cure or relapse, without loss to follow-up. Per protocol sustained virologic response (SVR)12 rates were 98.1% (622/634) in the full cohort and 97.9% (571/583) among treatment eligible patients. Exact logistic regression revealed no specific patient characteristics associated with relapse. Our meta-analysis of 6 additional real world cohorts, comprised of 5,637 patients, demonstrated similar risk for relapse between 8 weeks and 12 weeks of LDV/SOF (RR=0.99, 95% CI 0.98-1.00). An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patients. Greater utilization of this regimen is recommended. This article is protected by copyright. All rights reserved. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 25% |
| United States | 3 | 25% |
| United Kingdom | 1 | 8% |
| Singapore | 1 | 8% |
| Unknown | 4 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 4 | 33% |
| Members of the public | 4 | 33% |
| Scientists | 3 | 25% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 68 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 8 | 12% |
| Student > Master | 8 | 12% |
| Researcher | 7 | 10% |
| Student > Postgraduate | 4 | 6% |
| Student > Bachelor | 4 | 6% |
| Other | 15 | 22% |
| Unknown | 22 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 49% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Unspecified | 1 | 1% |
| Other | 3 | 4% |
| Unknown | 24 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2017.
All research outputs
#5,405,477
of 25,374,647 outputs
Outputs from Hepatology
#2,486
of 9,093 outputs
Outputs of similar age
#88,703
of 323,919 outputs
Outputs of similar age from Hepatology
#37
of 95 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,093 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,919 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.